Lantheus Holdings, Inc. and Novavax, Inc.: SG&A Spending Patterns Compared

SG&A Spending Trends: Lantheus Holdings vs. Novavax

In the ever-evolving landscape of the healthcare industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Lantheus Holdings, Inc. and Novavax, Inc. over the past decade. From 2014 to 2023, Lantheus Holdings has seen a steady increase in SG&A spending, peaking at approximately $267 million in 2023, a 270% rise from 2014. In contrast, Novavax's SG&A expenses surged dramatically, especially post-2020, reaching nearly $469 million in 2023, marking an astounding 2,255% increase from 2014. This stark contrast highlights Novavax's aggressive expansion and marketing strategies, likely fueled by its pivotal role in vaccine development during the COVID-19 pandemic. Meanwhile, Lantheus's more measured growth reflects a stable, consistent approach. These insights offer a window into the strategic priorities and market positioning of these two influential companies.